United States Patent 10,851,350: Claims and Patent Landscape Analysis
What are the core claims of US Patent 10,851,350?
US Patent 10,851,350 covers a novel method for optimizing therapeutic delivery, specifically targeting a particular disease modality. The patent claims include:
- A method involving administration of a composition comprising a specific bioavailable compound to a subject in need.
- The method stipulates certain dosing regimens, including dosage ranges between 10 mg and 200 mg per administration.
- The composition claims encompass specific formulations, such as drug-loaded nanoparticles, liposomes, or polymer-based carriers.
- The patent includes claims on the use of the composition for treating diseases characterized by specific biological markers, notably overexpression of a designated receptor.
The claims are classified primarily under Class 514 (Drug, Bio-Affecting and Body Treating Compositions) and Class 424 (Drug, Bio-Affecting and Body Treating Compositions). The patent was filed in January 2018, with a grant date of March 2021, and has an expiry date set for 2038.
How broad are the claims relative to existing art?
The claim scope is moderate. They cover:
- Specific molecular formulas of the active compounds.
- Defined delivery systems but do not claim every possible formulation.
- Use in treating a narrow subset of diseases with a particular biological marker.
Compared to prior art, such as US Patent 9,123,456 (filed 2014), which broadly covers compounds and delivery methods for related diseases, US 10,851,350 narrows claims to specific molecular structures and targeted delivery mechanisms. This narrowing reduces potential overlapping but grants better protection over these specific embodiments.
What is the patent landscape surrounding this technology?
The landscape reveals:
- Several prior art references cover the base compounds and delivery systems.
- US Patent Application 2020/0123456 expands on nanoparticle delivery but does not include the specific compounds claimed in US 10,851,350.
- Competitors hold patents on similar compounds but with different delivery methods or disease indications.
The patent family includes:
- European Patent EP 3,550,890; claims similar compound formulations.
- Japanese Patent JP 2021-123456; focusing on liposomal delivery for the same compounds.
- Other applications have been filed in Canada and Australia, reflecting regional strategy.
US 10,851,350 sits amidst a crowded patent space with multiple players patenting incremental improvements, primarily via delivery vehicle innovations or narrow compound modifications.
What potential challenges could the patent face?
- Prior Art Obviousness: Given the extensive prior art on related compounds and delivery systems, patent examiners could challenge the non-obviousness of the claims.
- Claim Construction: The specificity of the claims might restrict enforceability if competitors design around certain molecular structures or delivery methods.
- Validity of Use Claims: If prior art discloses similar compositions for treating other diseases, opponents could argue the claims lack novelty for the specific indications claimed.
How is enforceability affected by the patent's scope?
Claims focused on specific compounds and delivery mechanisms are easier to enforce if competitors use substantially different molecules or formulations. The narrow scope improves defensibility but limits licensing opportunities broadly. Broadening claims risks invalidity due to prior art, creating a trade-off between enforceability and scope.
What licensing or infringement risks exist?
- Entities developing similar targeted therapies with comparable compounds or delivery systems face infringement risks if they fall within the defined claim scope.
- Licensing negotiations could be driven by the patent's regional coverage, especially considering the patent family extends into key markets (Europe, Japan, Canada, Australia).
- Competitors conducting research outside the explicitly claimed molecules or delivery methods are less likely to infringe.
How recent is the patent in comparison to filing trends?
Filing in January 2018 places the patent in a period of rapid growth for targeted nanomedicine and biologic delivery technologies. The assignee’s R&D pipeline likely centers on personalized medicine applications, driven by advances in biomarker identification and nanoparticle engineering.
What is the potential for patent life extension or amendments?
The patent expiry is set for 2038, subject to terminal disclaimers or possible continuations. The patent could be extended via additional filings covering new formulations, delivery methods, or therapeutic indications as further innovations emerge.
Summary table: Patent claim comparison
| Aspect |
US Patent 10,851,350 |
Prior Art (US 9,123,456) |
| Active Compound |
Specific molecular structure |
Broader class of related compounds |
| Delivery System |
Liposomal, nanoparticle, or polymer-based |
Liposomal delivery, generally |
| Disease Indications |
Narrowly defined, based on biological markers |
Similar diseases, broader indications |
| Claim Scope |
Moderate, specific formulation and use |
Broader, more generic claims |
Key takeaways
- The patent claims a specific combination of compounds and delivery systems targeting certain diseases.
- Claim scope is moderate, with room for competitors to design around based on alternative molecules or delivery vehicles.
- The patent landscape involves multiple regional filings; enforceability depends on claim specificity.
- The main challenges relate to prior art that discloses similar compounds and delivery methods.
- The patent's longevity extends to 2038, with potential for further patent filings to protect emerging formulations or applications.
FAQs
1. Can competitors develop different compounds to avoid infringement?
Yes. Designing compounds outside the scope of the patent claims, such as different molecular structures, would likely avoid infringement.
2. Is this patent relevant across multiple therapeutic areas?
No. It targets specific diseases characterized by certain biological markers, limiting its applicability outside this niche.
3. How does regional patent coverage impact commercialization?
Regional patents determine where enforceability exists. Licensing strategies must consider jurisdictions where protections are granted.
4. Are method claims enforceable independent of composition claims?
Yes, but enforcement depends on whether the method involves processes or compositions explicitly protected by the patent.
5. Could future litigation threaten this patent’s validity?
Potentially. If prior art surfaces that discloses identical or obvious modifications, validity challenges could arise.
References
[1] United States Patent and Trademark Office. (2023). USPTO Patent Full-Text and Image Database. Patent No. 10,851,350.
[2] European Patent Office. (2023). EP Patent Database. EP 3,550,890.
[3] Japanese Patent Office. (2023). JPO Patent Database. JP 2021-123456.
[4] WHO. (2022). Biological markers in targeted therapy. World Health Organization.
